Yeast Cell Lines Research Articles

Is gamma-actin a regulator of amino acid transport?

A mutated yeast cell line incapable of growth in minimal medium with proline as the sole nitrogen source was restored to normal growth by transfection with a cDNA from mouse Ehrlich cells. The cloned cDNA (E51) was found to be 90% homologous to gamma-actin. Immediately after transfection with E51 cDNA, both alpha-aminoisobutyric acid (AIB) and proline uptake in the mutated yeast were increased, particularly at pH 5. The expression of the same E51 cDNA also enhanced amino acid uptake in Xenopus laevis oocytes after injection into the Xenopus nuclei. A mutated mammalian lymphocyte cell line (GF-17), deficient in system A transport, also showed increased Na(+)-dependent transport after transfection with E51 cDNA. Whereas the mock transfected GF-17 cells failed to grow in the selection medium, the transfectants with E51 cDNA grew better than the untransfected cells. The data are consistent with the conclusion that expression of E51 cDNA can modify inactive, endogenous amino acid transporters, permitting substantial amino acid uptake in cells deficient in amino acid transporter(s) and permitting rapid cell growth. The data suggest that the gamma-actin-like protein coded for by E51 cDNA may play a significant regulatory role in amino acid transport.

The 26S proteasome degrades mouse and yeast ornithine decarboxylase in yeast cells

Eukaryotic cells possess two high-molecular-mass proteases, the 700 kDa, 20S proteasome, as well as the even larger 1,400 kDa, 26S proteasome. It has been demonstrated that ornithine decarboxylase is degraded, in vitro, by the 26S proteasome that contains the 20S protease as its catalytic core, but not by the free 20S proteasome. Recently, by demonstrating severe inhibition of mouse and yeast ODC degradation in a mutant yeast cell line, defective in the chymotripsin-like activity of the yeast 20S proteasome, we implicated the 20S proteasome in the degradation of ODC, in vivo, in yeast cells. Here we show that the degradation of ODC is also severely inhibited in the mutant yeast cell lines, cim3-1 and cim5-1 containing a specific lesion in subunits that are unique to the yeast 26S proteasome. We therefore, conclude, that as illustrated in vitro, also in intact cells, it is the 26S proteasome, not the free 20S proteasome, that degrades ODC. We also demonstrate, that while deficiency in the proteasome chymotrypsine-like activity (in the yeast pre1-1 mutant) inhibits the degradation of both yeast and mouse ODCS, deficiency in the peptidyl-glutamyl-peptide-hydrolyzing (PGPH) activity inhibits only yeast ODC degradation. Similarly, we have noted that whereas the putative ATPase activity of both the CIM3 and CIM5 subunits is essential for the degradation of mouse ODC, only that of the CIM3 subunit is required for the degradation of yeast ODC. These results suggest differential utilization of individual proteasomal subunits in the recognition and degradation of individual short-lived proteins.

The 20S proteasome mediates the degradation of mouse and yeast ornithine decarboxylase in yeast cells

Ornithine decarboxylase (ODC), a key enzyme in the biosynthesis of polyamines, is one of the most rapidly degraded proteins in mammalian cells. Recently it has been demonstrated that mammalian ODC is degraded in vitro by the 26S protease that contains the 20S proteasome as its catalytic core, in a reaction that does not require ubiquitin. Here, we show that yeast and mouse ODC are both rapidly degraded in yeast cells and that their degradation severely inhibited in a mutant yeast cell line defective in the chymotryptic activity of proteinase yscE, the yeast 20S proteasome. These results provide compelling genetic support to previous biochemical studies suggesting the involvement of the 20S proteasome in the degradation of ornithine decarboxylase.

Mechanisms of oxygen radiosensitization in irradiated yeast. I. DNA double-strand breakage.

The relative contributions of the OH-mediated and direct radiation effect on the induction of DNA double-strand breaks (dsbs) were evaluated in two haploid yeast cell lines (GSH+ and gsh-) irradiated under oxic or hypoxic conditions in the absence or presence of 6 M glycerol as an OH radical scavenger. Gsh- cells are deficient in glutathione (GSH) biosynthesis, their GSH content is only 2% compared with GSH+ cells. Similar relative contributions are observed for both cell lines. Under oxic irradiation conditions about 64% of the response can be attributed to the OH-mediated (or indirect) radiation effect, whereas in hypoxic cells the indirect effect is only about 45%. High oxygen enhancement ratios (OERs) are observed for the OH-mediated radiation effect (4.24 for GSH+, 2.70 for gsh- cells) and low OERs for the direct effect (1.66 for GSH+, 1.44 for gsh- cells). The weighted total (i.e. direct and indirect) OER is 2.74 (GSH+) and 2.03 (gsh-). The dependence of radiosensitization for double-strand breakage on oxygen concentration is characterized by three components whose K-values are 0.5, 4 and 20% oxygen for GSH+ cells and 0.45, 5 and 60% oxygen for gsh- cells. Evidence is presented that the first two components represent the radiosensitization by oxygen of the OH-mediated effect, whereas the third component, requiring the highest oxygen concentration for sensitization, represents the radiosensitization by the direct effect. GSH+ and gsh- cells show virtually the same K-values for the OH-mediated effect, but different K-values for the direct effect.

Potential Uses of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Children

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein necessary for the growth, differentiation, and function of cells of the granulocyte-macrophage lineage. This agent has been molecularly cloned and expressed in bacteria, yeast, and mammalian cell lines, providing a limitless source of the pure human protein for use in children. Here, we briefly review the discovery, biologic characterization, gene identification and cloning, and clinical experience to date with this new agent, focusing where possible on the use of recombinant GM-CSF in children.